NCT05625568View on ClinicalTrials.gov

Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

June 30, 2024

Conditions
Rett Syndrome
Interventions
DRUG

VYNT-0126

Liquid for oral administration once daily

DRUG

Placebo

Liquid for oral administration once daily

Sponsors

Lead Sponsor

Vyant Bio
All Listed Sponsors
lead

Vyant Bio

INDUSTRY

NCT05625568 - Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients | Biotech Hunter | Biotech Hunter